Working… Menu
Trial record 1 of 1 for:    NCT03318523
Previous Study | Return to List | Next Study

Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease (SPARK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03318523
Recruitment Status : Terminated (SPARK did not meet it's primary outcome measure for year 1 and failed to meet secondary outcome measures resulting in the development of BIIB054 (cinpanemab) for Parkinson's disease to be discontinued and SPARK study was closed.)
First Posted : October 24, 2017
Last Update Posted : June 21, 2021
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : October 26, 2020
Actual Study Completion Date : April 29, 2021